GAITHERSBURG, Md.—Microdosing specialist Xceleron announced an agreement with Neurocrine Biosciences for a multi-arm Phase 0 study that will evaluate preliminary pharmacokinetics (PK) and metabolism of five compounds. Xceleron will conduct clinical trials in Europe with accelerator mass spectrometry analysis completed at the company's GLP accredited laboratories in York, U.K.
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Loading Next Article...
Loading Next Article...


Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
Subscribe